Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Launch Strategy: Reinforce Safety Profiles In Asia – BIO Conference

This article was originally published in PharmAsia News

Executive Summary

ATLANTA - When organizers titled the "Asia as the Biosimilar Launch Pad" session at BIO, they meant it. Many of the panelists agreed that a good strategy for launching biosimilars in the U.S. is to first release the product in Asia or emerging markets to create a stronger safety profile for the U.S. approval application

You may also be interested in...



Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News

In the ever-evolving pharmaceutical world, where Big Pharma is increasingly seeing common goals in aligning with generic drug companies, GlaxoSmithKline and Dr. Reddy's Labs recently entered into a strategic alliance to reach out to untapped emerging markets for generic drugs. While it is apparent that large pharmaceutical companies see emerging markets as their next big bet, how are generic drug makers responding? To find out, PharmAsia News India bureau caught up with G.V. Prasad, vice chairman of Dr. Reddy's Labs, who shaped the future for his company, from generic drugs to researching new compounds.

Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News

In the ever-evolving pharmaceutical world, where Big Pharma is increasingly seeing common goals in aligning with generic drug companies, GlaxoSmithKline and Dr. Reddy's Labs recently entered into a strategic alliance to reach out to untapped emerging markets for generic drugs. While it is apparent that large pharmaceutical companies see emerging markets as their next big bet, how are generic drug makers responding? To find out, PharmAsia News India bureau caught up with G.V. Prasad, vice chairman of Dr. Reddy's Labs, who shaped the future for his company, from generic drugs to researching new compounds.

Biopharma Industry Slated As China Pillar Industry, But Key Domestic Support Missing

SHANGHAI - Biopharmaceuticals will take a share in the Chinese central government's RMB 62.8 billion ($9.18 billion) investment plan to facilitate 11 key projects during 2009 to 2010. China's State Council passed a policy in May to promote the biotech industry to develop it as one of China's pillar industries in the future

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC071712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel